EXACERBATION OF CHOROIDAL AND RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Explore this paper's citation graph
Summary
Retinal pigment epithelial atrophy and choroidal atrophy in neovascular AMD seem to be exacerbated by anti–vascular endothelial growth factor treatment.
- Type
- article
- Published
- 2014-07-01
- Cited by
- 77
- References
- 21
- OpenAlex
- https://openalex.org/W1979285901
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2605102
Keywords
Macular degeneration, Ranibizumab, Medicine, Atrophy, Retinal pigment epithelium
References
- Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes
- Spectral domain optical coherence tomographic imaging of geographic atrophy.
- Prevalence of age-related macular degeneration in the United States.
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results
- In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics.
- RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
- Targeted deletion of Vegfa in adult mice induces vision loss.
- Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED: A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration
- Optical coherence tomography.
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Neovascular Age-Related Macular Degeneration Using Spectral-Domain Optical Coherence Tomography
- PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)
- Incidence and progression of geographic atrophy: observations from a population-based cohort.
- A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
- The Epidemiology of Progression of Pure Geographic Atrophy. The Beaver Dam Eye Study
- Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images.
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris
- Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
- Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography.
- “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Cited by
- Stem cell based therapies for age-related macular degeneration: The promises and the challenges.
- A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
- Relationship of central choroidal thickness with age-related macular degeneration status.
- Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
- Choroidal Haller's and Sattler's Layer Thickness Measurement Using 3-Dimensional 1060-nm Optical Coherence Tomography
- Mechanism of PEDF promoting the proliferation of lens epithelial cells in human eyes.
- Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes
- Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
- Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept
- Regulation of signaling events involved in the pathophysiology of neovascular AMD
- Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review
- Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration
- SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC ANALYSIS OF HEALTHY RETINA IN BRANCH RETINAL VEIN OCCLUSION AND ITS RESPONSE TO ANTIANGIOGENIC THERAPY
- A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD.
- Pharmacology of the retinal pigment epithelium, the interface between retina and body system.
- Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels.
- ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT
- Visualizing retinal pigment epithelium phenotypes in the transition to atrophy in neovascular age-related macular degeneration
- Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents
Related papers
- PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB
- Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment
- Ranibizumab for neovascular age-related macular degeneration.
- Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration
- Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab
- Ranibizumab in neovascular age-related macular degeneration
- Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
- Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health
- Recent advances in intravitreal injection of ranibizumab for myopic choroidal neovascularization